Amylyx Pharmaceuticals, Inc. Selling, General and Administrative Expense
Amylyx Pharmaceuticals, Inc. (AMLX) reported Selling, General and Administrative Expense of $21.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $21.93M, a 40.19% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $16.17M, a 3.09% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $15.39M, a 9.97% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $16.17M, a 9.29% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2025 was $62.89M, a 45.00% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2024 was $114.33M, a 39.30% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2023 was $188.36M, a 48.16% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2022 was $127.13M, a 226.53% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.93M 10-Q · filed 2026-08-06 | $38.09M 10-Q · filed 2026-08-06 | $53.49M derived: sum of 3 quarters · filed 2026-08-06 | $69.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $16.17M 10-Q · filed 2026-05-07 | $31.56M derived: sum of 2 quarters · filed 2026-05-07 | $47.73M derived: sum of 3 quarters · filed 2026-05-07 | $63.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $15.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $31.56M derived: sum of 2 quarters · filed 2026-03-03 | $47.20M derived: sum of 3 quarters · filed 2026-08-06 | $62.89M 10-K · filed 2026-03-03 |
| 2025-09-30 | $16.17M 10-Q · filed 2025-11-06 | $31.81M derived: sum of 2 quarters · filed 2026-08-06 | $47.49M 10-Q · filed 2025-11-06 | $64.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $15.64M 10-Q · filed 2026-08-06 | $31.32M 10-Q · filed 2026-08-06 | $48.42M derived: sum of 3 quarters · filed 2026-08-06 | $66.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $15.68M 10-Q · filed 2026-05-07 | $32.78M derived: sum of 2 quarters · filed 2026-05-07 | $50.61M derived: sum of 3 quarters · filed 2026-05-07 | $72.26M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $17.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $34.92M derived: sum of 2 quarters · filed 2026-03-03 | $56.57M derived: sum of 3 quarters · filed 2026-03-03 | $114.33M 10-K · filed 2026-03-03 |
| 2024-09-30 | $17.83M 10-Q · filed 2025-11-06 | $39.48M derived: sum of 2 quarters · filed 2025-11-06 | $97.23M 10-Q · filed 2025-11-06 | $149.47M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $21.65M 10-Q · filed 2025-08-07 | $79.41M 10-Q · filed 2025-08-07 | $131.65M derived: sum of 3 quarters · filed 2025-08-07 | $180.37M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $57.76M 10-Q · filed 2025-05-08 | $110.00M derived: sum of 2 quarters · filed 2025-05-08 | $158.72M derived: sum of 3 quarters · filed 2025-05-08 | $202.11M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $52.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $100.96M derived: sum of 2 quarters · filed 2025-03-04 | $144.35M derived: sum of 3 quarters · filed 2025-03-04 | $188.36M 10-K · filed 2025-03-04 |
| 2023-09-30 | $48.72M 10-Q · filed 2024-11-07 | $92.11M derived: sum of 2 quarters · filed 2024-11-07 | $136.12M 10-Q · filed 2024-11-07 | $176.96M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $43.39M 10-Q · filed 2024-08-08 | $87.40M 10-Q · filed 2024-08-08 | $128.24M derived: sum of 3 quarters · filed 2024-08-08 | $158.18M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $44.01M 10-Q · filed 2024-05-09 | $84.85M derived: sum of 2 quarters · filed 2024-05-09 | $114.79M derived: sum of 3 quarters · filed 2024-05-09 | $144.78M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $40.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $70.78M derived: sum of 2 quarters · filed 2024-02-22 | $100.78M derived: sum of 3 quarters · filed 2024-02-22 | $127.13M 10-K · filed 2024-02-22 |
| 2022-09-30 | $29.94M 10-Q · filed 2023-11-09 | $59.93M derived: sum of 2 quarters · filed 2023-11-09 | $86.28M 10-Q · filed 2023-11-09 | $101.20M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $29.99M 10-Q · filed 2023-08-10 | $56.34M 10-Q · filed 2023-08-10 | $71.27M derived: sum of 3 quarters · filed 2024-02-22 | $81.61M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $26.35M 10-Q · filed 2023-05-11 | $41.27M derived: sum of 2 quarters · filed 2024-02-22 | $51.62M derived: sum of 3 quarters · filed 2024-02-22 | |
| 2021-12-31 | $14.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $25.27M derived: sum of 2 quarters · filed 2024-02-22 | $38.93M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $10.35M 10-Q · filed 2022-11-10 | $24.01M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |